Healthcare — CAR-T Therapy Moves Into Cancer Prevention, Eli Lilly Closes $3.25B Biotech Acquisition, and Trump's Psychedelics EO Stirs Regulatory Uncertainty

Healthcare · 2026-04-21

Today's healthcare landscape is defined by three converging forces: therapeutic paradigm shifts, pharma consolidation, and regulatory unpredictability. The most consequential development is early CAR-T trial data presented at AACR 2026 showing promise in preventing smoldering multiple myeloma from progressing — a conceptual leap from treating active cancer to intercepting it before it fully…